Minocycline foam - Foamix

Drug Profile

Minocycline foam - Foamix

Alternative Names: FMX 101; FMX 102; FMX 103; FXFM-244

Latest Information Update: 08 May 2017

Price : $50

At a glance

  • Originator Foamix
  • Class Amides; Antibacterials; Dimethylamines; Neuroprotectants; Small molecules; Tetracyclines
  • Mechanism of Action Protein 30S ribosomal subunit inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Acne vulgaris
  • Phase II Impetigo; Rosacea

Most Recent Events

  • 01 May 2017 Foamix plans two phase III trials for Rosacea in mid-2017 (NCT03142451)
  • 01 May 2017 Efficacy and adverse event data from two phase III trials (Trials 04 and 05) in Acne released by Foamix Pharmaceuticals
  • 01 May 2017 Foamix Pharmaceuticals completes the phase III Trial 04 and 05 trials in Acne in USA (NCT02815267) (NCT02815280)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top